As the Romanian start-up Solartium becomes Meditrina, Romania is set to benefit from the development potential of the international group Meditrina Pharmaceuticals after the acquisition of the Solartium start-up. Thus, Meditrina Pharmaceutical Group strengthens its presence in Romania and the Republic of Moldova.
In the current context, any activity aimed at developing the medical and pharmaceutical fields is a topic of interest to everyone. The acquisition of Solartium by the Meditrina Group shows the intention of a prestigious company on the pharmaceutical market in Romania to expand, but also brings a lot of opportunities for Romanian patients and doctors.
Solartium’s vision combined with the research and development potential of Meditrina Pharmaceuticals provides a chance to bring forward innovation and a broad access to technology for better solutions in the pharmaceutical market.
Solartium, one of the most innovative start-ups in the pharmaceutical market has actively developed and consolidated its presence on the Romanian market in the last 12 years. Solartium had a constant increase in sales and market share thanks to the continuous launching of new products and innovative therapeutical approaches to several ailments. The strategic approach over the last years earned them a leading position in several segments like dermatology, urology, gynecology, and nephrology.
Meditrina Group, one of the fastest-growing pharmaceutical companies in South-Eastern Europe, has initiated a rebranding process of the companies that are part of the group, thus, starting March this year, SOLARTIUM GROUP SRL will become MEDITRINA PHARMACEUTICALS SRL.
“The name change from Solartium to Meditrina Pharmaceuticals means more than a new name: it sends a clear message to the market that we are a strong group that wants to highlight its role as an innovator and provider of pharmaceutical solutions. After 12 years in business, we remain true to our values and the mission we have been committed to since the beginning. Our achievements so far motivate us to accelerate the pace of progress, to constantly surpass ourselves and to remain a prestigious company in the pharmaceutical field in Romania”, says Massimo Bonsi, Founder and Managing Director Meditrina Pharmaceuticals in Romania and the Republic of Moldova.
Over the years, through a strategic partnership, Meditrina Group had an essential role in the evolution of Solartium’s business in Romania by facilitating access to strategic partnerships in the research and development area, contributing to the consolidation of the company’s position on the pharmaceutical market in Romania. After the acquisition, the benefits and the possibilities of development will exponentially grow.
Meditrina Pharmaceuticals Romania represents the most important part of the group, both in terms of revenues and profit and will maintain, in the coming years, its role as a strategic partner in the development of the group’s businesses.